I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.

Autor: Ou SH; Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange, CA 92868, United States; Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, United States. Electronic address: Ignatius.ou@uci.edu., Greenbowe J; Foundation Medicine Inc., 150 Second Street, Cambridge, MA 02141, United States., Khan ZU; Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange, CA 92868, United States; Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, United States., Azada MC; Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange, CA 92868, United States; Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, United States., Ross JS; Foundation Medicine Inc., 150 Second Street, Cambridge, MA 02141, United States; Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY 12208, United States., Stevens PJ; Foundation Medicine Inc., 150 Second Street, Cambridge, MA 02141, United States., Ali SM; Foundation Medicine Inc., 150 Second Street, Cambridge, MA 02141, United States., Miller VA; Foundation Medicine Inc., 150 Second Street, Cambridge, MA 02141, United States., Gitlitz B; USC Norris Comprehensive Cancer Center and Hospital, Department of Medicine, Division of Medical Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, United States.
Jazyk: angličtina
Zdroj: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2015 May; Vol. 88 (2), pp. 231-4. Date of Electronic Publication: 2015 Feb 12.
DOI: 10.1016/j.lungcan.2015.02.005
Abstrakt: Objectives: Acquired resistance mutations to anaplastic lymphoma kinase (ALK) inhibitors such as crizotinib and alectinib have been documented in non-small cell lung cancer (NSCLC) patients harboring ALK rearrangement (ALK+). Of note I1171T/N/S mutations in the ALK kinase domain have recently been described by several groups to confer resistance to alectinib, a second-generation ALK inhibitor. Additionally one of these reports demonstrated one ALK+ NSCLC patient harboring an I1171T acquired mutation has responded to ceritinib, another second-generation ALK inhibitor.
Materials and Methods: We reported the presence of an ALK I1171N resistance mutation from comprehensive genomic profiling from a liver biopsy of a progressing metastatic lesion in an ALK+ patient on alectinib after an initial partial response. The patient then responded to ceritinib 750 mg orally once daily but required dose reduction to 600 mg once daily. She initially had grade 3 elevation of liver enzymes from crizotinib necessitating the original switch to alectinib but experienced no transaminase elevations with alectinib or ceritinib.
Conclusions: This is the fifth patient case to date demonstrating that ALK I1171 mutation confers resistance to alectinib and the second reported case of ALK I1171 mutation being sensitivity to ceritinib. Substitutions of isoleucine at amino acid 1171 in the ALK kinase domain may distinguish which second generation ALK inhibitor will be effective after crizotinib failure. This case also provides evidence that transaminase elevations is likely a unique adverse event associated with crizotinib and unlikely a "class" effect involving all ALK inhibitors.
(Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: